Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2929–2952 of 13,629 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatoses Clear all

Conditions: Cushing's Syndrome
Interventions: mifepristone; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 15
States / cities: Birmingham, Alabama • Escondido, California • Stanford, California + 12 more

Conditions: Breast Cancer
Interventions: RECONJOINT; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more

Conditions: Acne Vulgaris
Interventions: Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel, DUAC® Gel, Placebo; Drug
Lead sponsor: Zydus Lifesciences Limited; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 12
States / cities: Dinuba, California • Santa Ana, California • Boynton Beach, Florida + 9 more

Conditions: Warts, Warts Hand, Verruca
Interventions: CellFX Device; Device
Lead sponsor: Pulse Biosciences, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 5
States / cities: Scottsdale, Arizona • San Diego, California • Rochester, New York + 2 more

Conditions: Alopecia Areata
Interventions: Placebo, SADBE 5%; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 12 Years to 18 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 42
States / cities: Scottsdale, Arizona • Fountain Valley, California • Fremont, California + 36 more

Conditions: Neoadjuvant Therapy, Chemotherapy, Hormone Replacement Therapy, Breast Cancer
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Recurrent Melanoma, Stage IIB Melanoma (Locally Advanced), Stage IIC Melanoma (Locally Advanced), Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma (Limited, Resectable)
Interventions: dabrafenib, trametinib, laboratory biomarker analysis; Drug · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Breast Cancer, Cancer Survivor
Interventions: educational intervention, counseling intervention, standard follow-up care, quality-of-life assessment, questionnaire administration; Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 2
States / cities: Duarte, California • Lancaster, California

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Provista Diagnostics, Inc; Industry
Eligibility: 25 Years to 75 Years · Female only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 12
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 8 more

Conditions: Metastatic Breast Cancer
Interventions: Trastuzumab emtansine [Kadcyla]; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: Not listed
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 40
States / cities: Little Rock, Arkansas • Denver, Colorado • Washington D.C., District of Columbia + 34 more

Conditions: Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions: anastrozole, gefitinib, fulvestrant, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Melanoma
Interventions: APX005M, Pembrolizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: 3-dimensional conformal accelerated partial breast irradiation; Radiation
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 45 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Breast Cancer, Breast Cancer, Female, Breast Cancer, Male, Breast Neoplasms
Interventions: Fluoro-D-glucose-positron Emission Tomography, 2-deoxy-2-[18F]fluoro-D-glucose (FDG), Echocardiogram; Diagnostic Test · Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hereditary Angioedema
Interventions: C1 Esterase Inhibitor, Placebo; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 6 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 17
States / cities: Granada Hills, California • Weston, Florida • Atlanta, Georgia + 14 more

Conditions: Breast Cancer, Osteoporosis
Interventions: biologic sample preservation procedure, dual x-ray absorptometry; Other · Procedure
Lead sponsor: NCIC Clinical Trials Group; Network
Eligibility: 35 Years and older · Female only
Enrollment: 238 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 13
States / cities: Torrance, California • Washington D.C., District of Columbia • Scarborough, Maine + 9 more

Conditions: Breast Cancer
Interventions: MR spectroscopy; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Skin Cancer
Interventions: Electronic + no text message, Electronic monitor + text messages; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Rosacea
Interventions: CGB-400; Drug
Lead sponsor: CAGE Bio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Fremont, California • San Diego, California • Edgewater, Florida

Conditions: Lipodystrophy
Interventions: Metreleptin; Biological
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 14 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Psoriasis
Interventions: GSK2894512 cream, Vehicle cream, Positive control, Negative control; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Community-Acquired MRSA Infections, Abscesses, Cellulitis, Folliculitis
Interventions: Mupirocin (drug); Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 17 Years to 60 Years
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Stage III or Stage IV Melanoma
Interventions: CADI-05; Biological
Lead sponsor: Cadila Pharnmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Allentown, Pennsylvania

Search by objective public record fields.

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

A Study of a Decision Tool for People Considering Breast Reconstruction Surgery

To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel

CellFX System for the Treatment of Cutaneous Non-Genital Warts

Study Evaluating Efficacy of Topical Squaric Acid Dibutyl Ester in Children and Adolescents With Alopecia Areata

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

The Use of Molecular Breast Imaging in the Evaluation of Tumor Response to Neoadjuvant Therapy in Women With Breast Cancer

Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery

Survivorship Care Planning in Improving the Quality of Life in Breast Cancer Survivors

Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer

APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

Radiation Therapy Using Gold Markers in Treating Women With Early-Stage Breast Cancer

PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient

Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks

Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3

Monitoring Response to Neoadjuvant Chemotherapy by the Use of Breast Proton MR Spectroscopy

Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use

CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes

Short-term Effects of Leptin in People With Lipodystrophy

A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects

An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection in Soldiers

Safety Study of CADI-05 in Patients With Advanced Stage Melanoma